China
Africa
Explore chapters and articles related to this topic
The Role of Cannabis and Cannabinoids in Pain Management
Published in Mark V. Boswell, B. Eliot Cole, Weiner's Pain Management, 2005
HU-308 is another agent emerging from the research of Raphael Mechoulam’s laboratories in Israel. It is a synthetic and specific CB2 agonist demonstrating no cannabinoid behavioral effects in laboratory animals (Hanus et al., 1999). Its pharmacological properties include inhibition of forskolin-stimulated cyclic AMP production, blood pressure reduction, inhibition of defecation, and production of peripheral analgesia with anti-inflammatory effects. An important therapeutic role for HU-308 as a peripherally acting agent may eventuate on further testing.
Cannabis and the Cornea
Published in Ocular Immunology and Inflammation, 2021
While CB1 regulates attractive chemotaxis of CECs, CB2 would modulate repulsive chemotaxis by activating MAPK and raising the cAMP levels. HU-308 is an example of CB2 agonist, as its antinociceptive effects were halted in CB2-/- mice. CB2 activation accelerates wound healing in injured murine corneas. By subjecting bovine corneal epithelial cells with a CB2R agonist (JWH133), Murataeva further discovered that active CB2R promotes MAPK activation, ERK phosphorylation, adenylyl cyclase activity, and cAMP quantities, without affecting the proliferation of corneal epithelial cells.
Cannabinoids and bone regeneration
Published in Drug Metabolism Reviews, 2019
Dragos Apostu, Ondine Lucaciu, Alexandru Mester, Horea Benea, Daniel Oltean-Dan, Florin Onisor, Mihaela Baciut, Simion Bran
HU-433 is a newer antagonist for CB-2 receptor, but with a lower affinity compared to HU-308 (Smoum et al. 2015). Results showed that it is three to four times more potent in producing osteoblast proliferation, osteoclast apoptosis and preventing osteoporosis in ovariectomized animal model (Smoum et al. 2015).